^
Association details:
Biomarker:ATM mutation
Cancer:Small Lymphocytic Lymphoma
Drug Class:T-lymphocyte cell therapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Anti-CD19 Chimeric Antigen Receptor T Cell Treatment of Relapsed /Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant to Bruton's Tyrosine Kinase (BTK) Inhibitor

Published date:
11/04/2020
Excerpt:
CLL/SLL IV stage, ATM (11q22) deletion, D13S25 (13q14. 3) positive, CD19 positive….Relapse of CLL/SLL occurred again after four months and at this stage the patient was considered for therapy in a clinical trial of CD19-specific chimeric antigen receptor (CAR-) T cell therapy....After treatment with CAR T 19 cell therapy for 53 months, the patient remained disease-free, the patient's lymph nodes, lymphocytes and Immunoglobulins were normal.
DOI:
10.1182/blood-2020-143099